MonthlyUpdate—Central & Peripheral Nervous Systems: Pharmacotherapeutic Potential for Compounds Acting at NMDA Receptors: Update 1995

References

• VENDER JR, NAIR SN, LEHMANN JC: NMDA receptors: The a.first decade. Exp. Opin. Invest. Drugs (1994) 3:1-14. A very comprehensive, well-balanced overview, with complete collection of key compounds.
   Google Scholar
• FOUTZ AS, PIERREFICHE 0, DENAVIT-SAUBIE M: Com- bined blockade of NMDA and non-NMDA receptors produces respiratory arrest in the adult cat. Neuroreport (1994) 5:481-484. Important issues concerning side-effects and the potential compli-cations of anti-glutamate polyphannacology.
   Google Scholar
• MCMANIGLE JE, TAVEIRA DASILVA AM, DRETCHEN ICL, GILLIS RA: Potentiation of MK-801-induced breathing Impairment by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. Eur.J. Pharmacol. (1994) 252:11–17.
   PubMed Web of Science ®Google Scholar
• PARPURA V, BASARSICY TA, LIU F, JEFTINIJA K, JEFTINIJA S, HAYDON PG: Glutamate-mediated astrocyte-neuron signalling. Nature (1994) 369:744-747. Novel study of frequently overlooked interaction. GO
   Google Scholar
• LIPTON SA, ROSENBERG PA: Excitatory amino acids as a final common pathway for neurologic disorders. New EngL J. Med. (1994) 330:613-622. Comprehensive if somewhat speculative overview of therapeutic potential for antagonists of excitatory amino acids.
   Google Scholar
• HOLLMANN M, HEINEMANN S: Cloned glutamate receptors. Ann. Rev. Neurosci. (1994) 17:31-108. Excellent and comprehensive molecular biology overview.
   Google Scholar
• MCBAIN CJ, MAYER ML: N-Methyl-D-aspartic acid recep- •tor structure andfunction. Physiol. Rev. (1994) 74:723-758.Excellent, comprehensive overview of NMDA receptors in multidis-ciplinary approach.
   Google Scholar
• SCHOEPFER R, MONYER H, SOMMER B, WISDEN W,SPRENGEL R, KUNER T, LOMELI H, HERB A, KOHLER M, BURNASHEV N: Molecular biology of glutamate recep-tors. Prog. Neurobtol. (1994) 42:353–357.
   PubMed Web of Science ®Google Scholar
• COSTA E, ARMSTRONG DM, GUIDOTTI A, KHARLAMOV A, KIEDROWSKI L, MANEV H, POLO A, WROBLEWSKI JT: Gangliosides in the protection against glutamate exci-totoxicity. Prog. Brain Res. (1994) 101:357–373.
   PubMed Web of Science ®Google Scholar
• FAROOQUI AA, HORROCKS LA: Involvement of glutamate receptors, lipases, and phospholipases in long-term potentiation and neurodegeneration [Review]. I Neurosci. Res. (1994) 38:6-11. Good discussion of second messenger mechanisms.
   Google Scholar
• HOSSMANN KA: Glutamate-mediated injury in focal •cerebral ischemia: the excitotoxin hypothesis revised.Brain Pathol. (1994) 4:23-36. Unorthodox but well-argued hypothesis concerning mechanisms underlying glutamate-mediated ischaemic injury.
   Google Scholar
• SODERLING TR, TAN SE, MCGLADE-MCCULLOH E, YAMAMOTO H, FUKUNAGA K: Excitatory interactions between glutamate receptors and protein kinases. J. Neurobiol. (1994) 25:304-311. Important findings concerning intracellular mechanism of modula-tion of postsynaptic NMDA receptor sensitivity.
   Google Scholar
• INGRAM DK, SPANGLER EL, IIJIMA S, KUO H, BRESNAHANEL, GREIG NH, LONDON ED: New pharmacological strategies for cognitive enhancement using a rat model of age-related memory impairment. Ann. N.Y. Acad. Sci. (1994) 717:16–32.
   PubMed Web of Science ®Google Scholar
• KRUEGER G: Amyotrophic lateral sclerosis: is excito-toxicity the key? Can. Med. Assoc. J. (1994) 151:441–443.
   PubMed Web of Science ®Google Scholar
• BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl. J. Med. (1994) 330:585–591.
   Google Scholar
• GREENBERG DA: Glutamate and Parkinson's disease.
   Google Scholar
• •Ann. Neurol. (1994) 35:639. Concise, insightful discussion with good selection of references.
   Google Scholar
• GREENAMYRE JT, ELLER RV, ZHANG Z, OVADIA A, KUR-LAN R, GASH DM: Antiparkinsonian effects of re-macemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. (1994) 35:655–661.
   PubMed Web of Science ®Google Scholar
• KIM JS, KORNHUBER HH, HOLZMULLER B, SCHMID-BURGK W, MERGNER T, KRZEPINSKI G: Reduction of cerebrospinal fluid glutamic add in Huntington's cho-rea and in schizophrenic patients. Arch. Psychiat. Ner-venkr. (1980) 228:7–10.
   PubMedGoogle Scholar
• KIM JS, KORNHUBER HH, SCHMID-BURGK W, HOLZMULLER B: Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. (1980) 20:379–382.
   PubMed Web of Science ®Google Scholar
• ISHIMARU M, KURUMAJI A, TORU M: Increases in strych-nine-Insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hy-pothesis. Biol. Psychiatry (1994) 35:84-95. Further evidence for potential role of glycine site in schizophrenia.
   Google Scholar
• JAVITT DC, ZYLBERMAN I, ZUKIN SR, HERESCO-LEVY U, LINDENMAYER JP: Amelioration of negative symptoms In schizophrenia by glycine. Am. J. Psych. (1994) 151:1234–1236.
   PubMed Web of Science ®Google Scholar
• KAY SR, FISZBEIN A, OPLER LA: The positive and negativesyndrome scale (PANSS) for schizophrenia. Schizophr. Bull. (1987) 13:261–276.
   PubMed Web of Science ®Google Scholar
• WIESER HG: Zurich Consensus Conference on New Antiepileptic Drugs. Introduction: goals. Epi (1994) 35\(Suppl. 5):S1–S5.
   Google Scholar
• MELDRUM BS: The role of glutamate in epilepsy and other CNS disorders. Neurol. (1994) 44\(Suppl. 8):S14–S23.
   Google Scholar
• COFFIN V, COHEN-WILLIAMS M, BARNET T A: Selective antagonism of the anticonvulsant effects of felbamate by glycine. Eur. J. Pharmacol. (1994) 256:R9–10.
   PubMed Web of Science ®Google Scholar
• TRUBE G, NETZER R: Dextromethorphan: cellular effects reducing neuronal hyperactivity. Epi (1994) 35(Suppl.): S62–S67.
   Google Scholar
• Saimrrr B, NETZER R, FANCONI S, BAUMANN P, BOLT-SHAUSER E: Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients. J. Neurol. Neurosurg. Psych. (1994) 57:333–339.
   PubMed Web of Science ®Google Scholar
• FERKANY JW, BOROSKY SA, CLISSOLD DV, PONTECORVO MJ: Dextromethorphan inhibits NMDA-induced convul-sions. Eur. J. Pharmacol. (1988) 151:151–154.
   PubMed Web of Science ®Google Scholar
• FISHER MKJONES S, SACCO RE: Prophylactic neuropro-tection for cerebral ischemia. Stroke (1994) 25:1075–1080.
   PubMed Web of Science ®Google Scholar
• ALBERS G'37, ATKINSON RP, KELEY RE, ROSENBAUM DM:Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke (1994) 26:254–258.
   Web of Science ®Google Scholar
• GAONI Y, CHAPMAN AG, PARVEZ N, POOK PC, JANE DE,WATIUNS JC: Synthesis, NMDA receptor antagonist ac-tivity, and anticonvulsant action of 1-aminocyclobu-tanecarboxylic add derivatives. J. Med. Chem. (1994) 37:4288–4296.
   PubMedGoogle Scholar
• MCCABE RT, WASTERLAIN CG, KUCHARCZYK N, SOFIARD, VOGEL JR: Evidence for anticonvulsant and neuro-protectant action of felbamate mediated by strychnine-insensitive glycine receptors. J. Pharmacol. Exp. Ther. (1993) 264:1248–1252.
   PubMed Web of Science ®Google Scholar
• SOFIA RD, GORDON R, GELS M, DIAMANTIS W: Compara-tive effects of felbamate and other compounds on N-methyl-D-aspartic add-induced convulsions and le-thality in mice. Pharmacol. Res. (1994) 29:139–144.
   PubMed Web of Science ®Google Scholar
• RHO JM, DONEVAN SD, ROGAWSKI MA: Mechanism of action of the anticonvulsant felbamate: opposing ef-fects on N-methyl-D-aspartate and gamma-ami-nobutyric acidA receptors. Ann. Neurology (1994) 35:229–234.
   PubMed Web of Science ®Google Scholar
• QUIRK K, FOSTER AC, MCKERNAN RM: Characterizationof the solubilized NMDA receptor complex from rat brain with [3H]L-689,560, a glycine site antagonist. Mol. Membr. Biol. (1994) 11:17–21.
   PubMed Web of Science ®Google Scholar
• QUARTERMAIN D, MOWER J, RAFFERTY MF, HERTING RL, LANTHORN TH: Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine fa-cilitates learning and retention. Eur. J. Pharmacol. (1994) 257:7-12. Explanation for the previously inconsistent findings with DCS in cognitive enhancement tests.
   Google Scholar
• BITON B, GRANGER P, CARREAU A, DEPOORTERE H, SCATTON B, AVENET P: The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca24" channels in rat cultured cortical neurons. Eur. J. Phar-macol. (1994) 257:297–301.
   Google Scholar
• LYSKO PG, WEBB CL, FEUERSTEIN G: Neuroprotective effects of carvedilol, a new antihypertensive, as a Na+ channel modulator and glutamate transport inhibitor. Neurosci. Lett. (1994) 171:77–80.
   PubMed Web of Science ®Google Scholar
• GREENAMYRE JT, GARCIA-OSUNA M, GREENE JG: The endogenous cofactors, thioctic add and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum. Neurosci. Lett. (1994) 171:17–20.
   PubMed Web of Science ®Google Scholar
• CHOW HS, LYNCH B, ROSE K, CHOI DW: Trolox attenu- ates cortical neuronal injury induced by iron, ultravio-let light, glucose deprivation, or AMPA. Brain Res. (1994) 639:102-108. Significant anti-peroxidative approach to NMDA-mediated excito-toxicity.
   Google Scholar
• PARK-CHUNG M, WV FS, FARB DH: 3 alpha-Hydroxy-5beta-pregnan-20-one sulfate: a negative modulator of the NMDA-induced current in cultured neurons. Mol. Pharmacol. (1994) 46:146–150.
   PubMed Web of Science ®Google Scholar
• ROMEO E, CHENEY DL, ZIVKOVIC I, COSTA E, GUIDOTTIA: Mitochondria' diazepam-binding inhibitor receptor complex agonists antagonize dizocilpine amnesia: pu-tative role for allopregnanolone. J. Pharmacol. Exp. 7her. (1994) 270:89–96.
   Google Scholar
• BULLER AL, LARSON HC, SCHNEIDER BE, BEATON JA,MORRIS= RA, MONAGHAN DT: The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition. J. Neurosci. (1994) 14:5471–5484.
   PubMed Web of Science ®Google Scholar
• MOON IS, APPERSON ML, KENNEDY MB: The major •tyrosine-phosphorylated protein in the postsynaptic density fraction is N-methyl-D-aspartate receptor subunit 2B. Proc . Natl. Acad. Sci. (USA)(1994) 91:3954-3958. Major finding concerning modulation of NMDA receptor sensitivity.
   Google Scholar
• WILLIAMS K, ZAPPIA AM, PRITCHETT DB, SHEN YM, MOLINOFF PB: Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol. Pharmacol. (1994) 45:803–809.
   PubMed Web of Science ®Google Scholar
• WANG YT, SALTER MW: Regulation of NMDA receptors by tyrosine ldnases and phosphatases. Nature (1994) 369:233-235. Significant biochemical insight into mechanism of short-term regu-lation of NMDA receptor sensitivity.
   Google Scholar
• LAURIE DJ, SEEBURG PH: Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA. J. Neurosci. (1994) 14:3180–3194.
   PubMed Web of Science ®Google Scholar
• OKAMOTO M, MORI S, ICHIMURA M, ENDO H: Chondroi-tin sulfate proteoglycans protect cultured rat's cortical and hippocampal neurons from delayed cell death induced by excitatory amino acids. Neurosci. Lett. (1994) 172:51–54.
   PubMed Web of Science ®Google Scholar
• MURPHY NP, CORDIER J, GLOWINSKI J, PREMONT J: Is protein kinase C activity required for the N-methyl-D-aspartate-evoked rise in cytosolic Ca2''' in mouse striatal neurons? Eur. J. Neurosci. (1994) 6:854–860.
   Web of Science ®Google Scholar
• WEISS S, HOCHMAN D, MACVICAR BA: Repeated NMDA receptor activation induces distinct intracellular cal-cium changes in subpopulations of striatal neurons in vitro. Brain Res. (1993) 627:63–71.
   PubMed Web of Science ®Google Scholar
• SNELL LD, IORIO KR, TABAKOFF B, HOFFMAN PL: Protein kinase C activation attenuates N-methyl-D-aspartate-in-duced increases in intracellular calcium in cerebellar granule cells. J. Neurocbem. (1994) 62:1783–1789.
   PubMed Web of Science ®Google Scholar
• LU 'YM, LU BF, ZHAO FQ, YAN YL, HO XP: Accumulation of glutamate is regulated by calcium and protein kinase C in rat hippocampal slices exposed to ischeraic states. Hippocampus (1993) 3:221–227.
   Google Scholar
• LIEBERMAN DN, MODY I: Regulation of NMDA channel •function by endogenous Ca(2+)-dependent phos-phatase. Nature (1994) 369:235-239. Significant findings concerning modulation of NMDA receptor sen-sitivity.
   Google Scholar
• WANG LY, ORSER BA, BRAUrIGAN DL, MACDONALD JF: Regulation of NMDA receptors in cultured hippocampal neurons by protein phosphatases 1 and 2A- Nature (1994) 369:230-232. Significant physiological evidence to support growing understanding of short-term regulation of NMDA receptor sensitivity.
   Google Scholar
• HENSHAW R, JENKINS BG, SCHULZ JB, FERRANTE RJ, KOWALL NW, ROSEN BR, BEAL MF: Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res. (1994) 647:161–166.
   PubMed Web of Science ®Google Scholar
• LIU H, WANG H, SHENG M, JAN LY, JAN YN, BASBAUM Al: Evidence for presynaptic N-methyl-D-aspartate autore-ceptors in the spinal cord dorsal horn. Proc . Natl. Acad. Sci. (USA) (1994) 91:8383–8387.
   PubMed Web of Science ®Google Scholar
• MANZONI 0j, MANABE T, NICOLL RA: Release of adeno-sine by activation of NMDA receptors in the hippocam-pus. Science (1994) 265:2098–2101.
   PubMed Web of Science ®Google Scholar
• WETMORE C, OLSON L, BEAN AJ: Regulation of brain-de-rived neurotrophic factor (BDNF) expression and re-lease from hippocampal neurons is mediated by non-NMDA type glutamate receptors. J. Neurosci. (1994) 14:1688–1700.
   PubMed Web of Science ®Google Scholar
• GANDOLFI 0, RIMONDINI R, DALL'OLIO R: D-cycloserine decreases both D1 and D2 dopamine receptors number and their function in rat brain. Pharmacol. Btochem. 13ehav. (1994) 48:351–356.
   Google Scholar
• DALL'OLIO R, IUMONDINI R, GANDOLFI 0: The NMDA positive modulator D-cycloserine inhibits dopamine-mediated behaviors in the rat. Neuropharmacol. (1994) 33:55-59. Potential evidence for antipsychotic application of DCS.
   Google Scholar
• QIN ZH, ZHOU LW, 'WEISS B: D2 dopamine receptor messenger RNA is altered to a greater extent by block-ade of glutamate receptors than by blockade of dopamine receptors. Neurosci. (1994) 60:97–114.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN LE, RASMUSSON AM, BUNNEY BS, ROTH RH: The NMDA glycine site antagonist (+)-HA-966 selectively regulates conditioned stress-induced metabolic activa-tion of the mesoprefrontal cortical dopamine but not serotonin systems: a behavioral, neuroendocrine, and neurochemical study in the rat. J. Neurosci. (1994) 14:4937–4950.
   PubMed Web of Science ®Google Scholar
• JEDEMA HP, MOGHADDAM B: Glutamatergic control of dopamine release during stress in the rat prefrontal cortex. J. Neurochem. (1994) 63:785–788.
   PubMed Web of Science ®Google Scholar
• DIXON JF, LOS GV, HOKIN LE: Lithium stimulates gluta- •mate 'release' and inosito11,4,5-ffisphosphate accumu-lation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc. Natl. Acad. Sci. (USA) (1994) 91:8358-8362. Novel hypothesis for mechanism of action of lithium in bipolar disorder.
   Google Scholar
• WATANABE A, HAMADA T, SHIBATA S, WATANABE S: Effects of nitric oxide synthase inhibitors on N-methyl-D-aspartate-induced phase delay of circadian rhythm of neuronal activity in the rat suprachiasmatic nucleus in vitro. Brain Res. (1994) 646:161–164.
   PubMed Web of Science ®Google Scholar
• PITKANEN M, SIRVIO J, LAHTINEN H, KOIVISTO E, RIEK- KINEN P: d-Cycloserine, a partial agonuist at the g,lycine site, enhances the excitability of dentate granule cells in vivo in rats. Eur. J. Pharmacol. (1994) 253:125-129. Demonstrates that glycine site is not fully occupied under physiologi-cal conditions.
   Google Scholar
• SHOAIB M, BENWELL ME, AKBAR MT, STOLERMAN IP, BALFOUR DJ: Behavioural and neurochemical adapta-tions to nicotine in rats: influence of NMDA antagonists. Br. J. Pharmacol. (1994) 111:1073–1080.
   PubMed Web of Science ®Google Scholar
• DURMULLER N, CRAGGS M, MELDRUM BS: The effect of sethe non-NMDA receptor antagonist GYKI 52466 andNBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. (1994) 17:167-174. Concise and comprehensive overview of glutamatergic compounds in development and their potential in treating epilepsy.
   Google Scholar
• WLAZ P, BARAN H, LOSCHER W: Effect of the gly-cine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice. Eur. J. Pharmacol. (1994) 257:217–225.
   PubMed Web of Science ®Google Scholar
• NORRIS DO, MASTROPAOLO J, O'CONNOR DA, COHEN JM, DEUTSCH SI: A glycinergic intervention potentiates the antiseizure efficacies of MK-801, fturazepam, and carbamazepine. Neurochem. Res. (1994) 19:161–165.
   PubMed Web of Science ®Google Scholar
• BROWN LM, LEE YP, TEYLER TJ: Antiepikptics inhibit cortical N-methyl-D-aspartate-evoked [311]no-repinephrine efflux. Eur. J. Pharmacol. (1994) 254:307–309.
   PubMed Web of Science ®Google Scholar
• HAUBER W, WALDENMEIER MT: The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic ef-fects of the competitive NMDA receptor antagonist CGP 37849. Eur.j Pharmacol. (1994) 256:339–342.
   PubMed Web of Science ®Google Scholar
• ZADOW B, SCHMIDT Wj: The AMPA antagonists NBQXand GYKI 52466 do not counteract newoleptic-induced catalepsy. Naunyn-SchmiedRberg's Arch . Pharmacol. (1994) 349:61–65.
   PubMed Web of Science ®Google Scholar
• GOETTL VM, LARSON AA: Antinodception induced by 3-((±) -2- carboxy- piperazin - 4 -y1) -propy1-1-phosphonic acid (CPP), an N-methyl-D-aspartate (NMDA) competi-tive antagonist, plus 6,7-dinitroquinoxaline-2,3-dione (DNQX), a non-NMDA antagonist, differs from that Induced by MK-801 plus DNQX. Brain Res. (1994) 642:334–338.
   PubMed Web of Science ®Google Scholar
• ELLIOTT K, MINAMI N, KOLESNIKOV YA, PASTERNAK GW, INTURRISI CE: The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase Inhibitor, NG-nitro-L-arghilne, attenuate analgesic tol-erance to the mu-opioid morphine but not to kappa opioids. Pain (1994) 56:69–75.
   PubMed Web of Science ®Google Scholar
• BULLOCK R, GRAHAM DI, SWANSON S, MCCULLOCH J: Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat. J. Cerebral Blood Flow & Metab. (1994) 14:466–471.
   PubMed Web of Science ®Google Scholar
• CIANI E, GUARNIERI T, CONTESTABILE A: Fos protein Induction, neuropathology, and pharmacological pro-tection after excitotoxic brain insult_ Exp. Brain Res. (1994) 98:421–430.
   Web of Science ®Google Scholar
• MIES G, KOHNO K, HOSSMANN KA: Prevention of purl-Infarct direct current shifts with glutamate antagonist NBQX following occlusion of the middle cerebral artery in the rat. J. Cerebral Blood Flow& Metab. (1994) 14:802–807.
   PubMed Web of Science ®Google Scholar
• AKANEYA Y, TAKAHASHI M, HATANAKA H: Death of cultured postnatal rat CNS neurons by in vitro hypoxia with special reference to N-methyl-D-aspartate-related toxicity. Neurosci. Res. (1994) 19:279–285.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO A, TAKEDA A, KOGURE K, ONODERA H: NMDA receptor (NMDAR1) expression in the rat hippo-campus after forebrain ischemia. Neurosci. Lett, (1994) 170:39–42.
   PubMed Web of Science ®Google Scholar
• DREYER EB, PAN ZH, STORM S, LIPTON SA: Greater sensitivity of larger retinal ganglion cells to NMDA-me-diated cell death. Neuroreport (1994) 5:629–631.
   PubMed Web of Science ®Google Scholar
• LIPPERT K, WELSCH M, KRIEGLSTEIN J: Over-additive protective effect of dizocilpine and NBQX against neuronal damage. Eur. J. Pharmacol. (1994) 253:207–213.
   PubMed Web of Science ®Google Scholar
• KAUBE H, GOADSBY PJ: Anti-migraine compounds fail to modulate the propagation of cortical spreading de-pression in the cat. Eur. Neurol. (1994) 34:30–35.
   PubMed Web of Science ®Google Scholar
• TSAI LH, TSAI W, WU Effect of L-glutamic add on add secretion and iffununohistochemical localization of glutamatergic neurons in the rat stomach. J. Neurosci. Res. (1994) 38:188–195.
   PubMed Web of Science ®Google Scholar
• FACCHINETTI F, DALL'OLIO R, GIANT E, SPARAPANI M, VLRGILI M, CONTESTABILE A: Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate re-ceptor through the competitive antagonist CGP 39551 In rats. Neurosci. (1994) 60:343–353.
   PubMed Web of Science ®Google Scholar
• AUER RN, COULTER KC: The nature and time course of •neuronal vacuolation induced by the N-methyl-D-aspar-tate antagonist MK-801. Acta Neuropathol. (Berlin) (1994) 87:1-7. Presents this potential negative side-effect, an issue given much importance by the FDA, in appropriate and balanced context.
   Google Scholar
• WATANABE M, MISHINA M, INOUE Y: Distinct distribu-tions of five NMDA receptor channel subunit mRNAs in the brainstem. J. Comp. Neurol. (1994) 343:520–531.
   PubMedGoogle Scholar